The Denmark-based global healthcare company Novo Nordisk, which has been a leader in the health sector for over 100 years and has improved patients' lives for 30 years in Türkiye, warned the public about the risks posed by counterfeit medicines, which have increased in recent times in the country.

During a meeting hosted by Dr. Ömer Buğra Bahadır, Senior Director of Clinical, Medical, and Regulatory Affairs for Novo Nordisk Turkey, and attended by Prof. Dr. Zeynep Oşar Siva, Vice President of the Turkish Diabetes Society, the current situation with counterfeit medicines was presented with data, highlighting the dangers posed to patients by medications not obtained from pharmacies.